Business Daily Media

Men's Weekly

.

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

  • Written by ACN Newswire - Press Releases
ADELAIDE, AU, Mar 12, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.

Atossa Therapeutics, Inc.

Read more //?#

Work-life Balance Key to Solving Construction Talent Shortage

New data from leading talent company Randstad Australia shows flexible working and work-life balance could be critical to addressing ongoing talen...

How to Apply for More Jobs in Less Time Using AI Automation

Most job seekers spend 11 to 14 hours per week on applications and still hear nothing back. That's not a motivation problem. That's a process proble...

Why Middle Australia Is Quietly Driving the Shift Away From Car Ownership

The narrative around changing attitudes to car ownership has long focused on Gen Z. Younger Australians are often portrayed as the generation movi...

Launchd Acquires WeAreTENZING as ANZ Creator Economy Spend Nears $1 Billion

Launchd, Australia's leading talent-first creator economy group, has acquired WeAreTENZING, one of New Zealand's most respected talent agencies, b...

Time to punch above our weight and stop shadowboxing on AI

Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...